Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1713468

	registered interest
	date	24/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Social Services: Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has issued recent guidance to integrated care boards on their role in assessing the mental and emotional health of young people entering care using a person qualified to assess mental health as part of the initial health assessment.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	23541
	answer	answer is ministerial correction date of answer 29/04/2024 answer text <p>The statutory guidance, Promoting the health and wellbeing of looked after children, published in 2015, reflects the requirement that the relevant local authority must make arrangements for the initial health assessment to be carried out by a registered medical professional who is suitably qualified to assess a young person's physical, emotional, and mental health needs.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 29/04/2024 16:29:40 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4616 label Biography information for Rosie Duffield

1695894

	registered interest
	date	13/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgical Mesh Implants: Compensation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what her planned timetable is for making a decision on redress for people affected by mesh implants following the publication of The Hughes Report on 7 February 2024.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	18548
	answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations, and will respond substantively in due course.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 18/03/2024 10:34:57 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4616 label Biography information for Rosie Duffield

1687063

	registered interest
	date	02/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Kent
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many adult social care residential care home places there were in (a) Kent and (b) Canterbury in each year since 2015.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	12842
	answer	answer is ministerial correction date of answer 07/02/2024 answer text <p>The Care Quality Commission (CQC) publish the CQC Care Directory annually, which lists the number of care home registrations in the adult social care sector. This includes the number of care home beds, with or without nursing. The following table shows the number of CQC registered care home beds for Kent, on 1 January of each year from 2015 onwards:</p><table><tbody><tr><td><p>Year</p></td><td><p>Registered Care Home Beds</p></td></tr><tr><td><p>2015</p></td><td><p>15,198</p></td></tr><tr><td><p>2016</p></td><td><p>15,131</p></td></tr><tr><td><p>2017</p></td><td><p>14,406</p></td></tr><tr><td><p>2018</p></td><td><p>14,590</p></td></tr><tr><td><p>2019</p></td><td><p>14,431</p></td></tr><tr><td><p>2020</p></td><td><p>14,610</p></td></tr><tr><td><p>2021</p></td><td><p>14,586</p></td></tr><tr><td><p>2022</p></td><td><p>14,598</p></td></tr><tr><td><p>2023</p></td><td><p>14,543</p></td></tr><tr><td><p>2024</p></td><td><p>14,638</p></td></tr></tbody></table><p> </p><p>The following table shows the number of care home beds for Canterbury, on 1 January of each year from 2015 onwards:</p><table><tbody><tr><td><p>Year</p></td><td><p>Registered Care Home Beds</p></td></tr><tr><td><p>2015</p></td><td><p>943</p></td></tr><tr><td><p>2016</p></td><td><p>980</p></td></tr><tr><td><p>2017</p></td><td><p>973</p></td></tr><tr><td><p>2018</p></td><td><p>981</p></td></tr><tr><td><p>2019</p></td><td><p>1,020</p></td></tr><tr><td><p>2020</p></td><td><p>1,025</p></td></tr><tr><td><p>2021</p></td><td><p>1,007</p></td></tr><tr><td><p>2022</p></td><td><p>984</p></td></tr><tr><td><p>2023</p></td><td><p>976</p></td></tr><tr><td><p>2024</p></td><td><p>1,087</p></td></tr></tbody></table><p>Note: This data is also from the CQC Care Directory but cross-referenced with postcode data to identify care home beds in Canterbury with or without nursing.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 07/02/2024 17:39:50 answering member 4527 label Biography information for Helen Whately
	tabling member	4616 label Biography information for Rosie Duffield

1684795

	registered interest
	date	24/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dental Services: Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential relationship between the availability of NHS dentistry appointments and patient access to bone-strengthening medication to treat cancer.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	11405
	answer	answer is ministerial correction date of answer 29/01/2024 answer text <p>Whilst the Department has not made a formal assessment, some integrated care boards (ICBs) may be looking at this, using the flexible commissioning model opportunity to meet the needs of their populations. Cancer services remain a priority for ICBs.</p><p>The Government has implemented a package of reforms to improve access to National Health Service dental care, which has had an effect with more patients being seen and a 23% increase in NHS activity in the past year. We know we need to do more, and the Department’s Dentistry Recovery Plan will be published shortly, setting out a big package of change.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 29/01/2024 09:47:26 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4616 label Biography information for Rosie Duffield

1682573

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Internet
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help prevent the online sale of prescription drugs without a prescription.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	9913
	answer	answer is ministerial correction date of answer 22/01/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the regulator in the United Kingdom for human medicines and is responsible for enforcing the Human Medicines Regulations 2012. The MHRA has identified the illegal sale and supply of human medicines as a global challenge. This includes the sale of prescription drugs from unregulated sources. Criminal gangs, often based overseas, advertise medicines through illicit websites resembling those of legitimate pharmacies, while others exploit online marketplaces or sell social media platforms.</p><p>The MHRA has a dedicated Criminal Enforcement Unit (CEU) that works with partners across government and policing to prevent and disrupt this illegal trade and to bring to justice those involved. The CEU monitors online channels for evidence of illegal activity and takes proportionate regulatory action. This includes using the full range of the Agency’s powers to investigate and prosecute offenders where necessary and appropriate. The unit also works to remove illegally trading websites and remove criminal profits from offenders. Through its #Fakemeds communications campaign, the MHRA also provides quick and easy tools to help the public avoid buying illegally traded medicines when they shop online.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/01/2024 09:45:00 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4616 label Biography information for Rosie Duffield

1663941

	registered interest
	date	13/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of ADHD medication.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	201794
	answer	answer is ministerial correction date of answer 18/10/2023 answer text <p>We are aware of supply issues affecting medicines used for the management of attention deficit hyperactivity disorder (ADHD). We have issued communications, in the form of a National Patient Safety Alert, to the National Health Service to advise healthcare professionals on management of patients during this time. We continue to work closely with manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom.</p> answering member constituency Colchester answering member printed Will Quince question first answered 18/10/2023 09:30:25 answering member 4423 label Biography information for Will Quince
	tabling member	4616 label Biography information for Rosie Duffield

1658202

	registered interest
	date	05/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Shingles: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the guidance issued by the NHS entitled Introduction of Shingrix® vaccine for the whole programme and expansion of eligible cohorts, published on 4 July 2023, on people who turned 65 before 1 September 2023.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	197821
	answer	answer is ministerial correction date of answer 12/09/2023 answer text <p>The Joint Committee on Vaccination and Immunisation advised the Government on the implementation of the Shingrix vaccine and the rollout of the cohort expansion. This advice was based on various considerations, including population impact. The Government accepted this advice, and it is the basis of NHS England guidance on the Shingles programme.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 12/09/2023 11:47:54 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4616 label Biography information for Rosie Duffield

1658222

	registered interest
	date	05/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Headaches: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of funding sphenopalatine ganglion block treatment on the NHS.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	197830
	answer	answer is ministerial correction date of answer 13/09/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) has not made an assessment.</p><p>NICE has published a clinical guideline (CG150) on the diagnosis and management of headaches in children aged over 12 years old and recommends several treatments for tension-type headache, migraine, cluster headache and medication overuse headache. If new evidence on the use of sphenopalatine ganglion block became available, then NICE would consider the impact it has on its current recommendations.</p><p> </p><p>NHS England also carefully reviewed the evidence to commission Sphenopalatine Ganglion Stimulation for Refractory Chronic Cluster Headache (Adults) in 2018, and concluded that there is not enough evidence to consider making the treatment available at this time. More information on the NHS evidence review is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/10/Sphenopalatine-Ganglion-Stimulation-for-Refractory-Chronic-Cluster-Headache-adults.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/10/Sphenopalatine-Ganglion-Stimulation-for-Refractory-Chronic-Cluster-Headache-adults.pdf</a></p><p> </p><p>NHS England can review this policy or consider a new policy for this treatment for a different clinical indication, in line with the published methods for clinical policy development, if a lead clinician considers that there is new published, peer reviewed evidence that should be considered.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/09/2023 16:44:16 answering member 4423 label Biography information for Will Quince
	tabling member	4616 label Biography information for Rosie Duffield

1646699

	registered interest
	date	22/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of the availability of covid-19 booster vaccines for people who are clinically vulnerable.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	190850
	answer	answer is ministerial correction date of answer 29/06/2023 answer text <p>The United Kingdom has sufficient supply of vaccines to meet the current advice from the Joint Committee on Vaccination and Immunisation for the 2023 spring and autumn booster campaigns. This includes agreements with Pfizer/BioNTech, Moderna, Sanofi/GSK and Novavax, which the Medicines and Healthcare products Regulatory Agency has approved for use in the UK. We remain in regular contact with the vaccine manufacturers to ensure the future supply of vaccines to the UK.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 29/06/2023 09:31:22 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4616 label Biography information for Rosie Duffield

1646700

	registered interest
	date	22/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of recognising people who have severe learning disabilities as being clinically vulnerable for the purposes of the eligibility criteria for covid-19 booster jabs.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	190851
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is the independent body made up of scientific and clinical experts who advise Government on which authorised vaccines the United Kingdom should use and which groups in the population should be offered initial or further doses of a particular vaccine.</p><p>The primary aim of the COVID-19 vaccination programme continues to be the prevention of severe disease, such as hospitalisation and mortality, arising from COVID-19. The JCVI identified at the start of the programme a number of groups in the population at high clinical risk of severe outcomes from COVID-19. One of these clinical risk groups covers those with chronic neurological disease. This includes all those with severe learning difficulties. The full list of conditions covered is defined in tables two and four of the UK Health Security Agency guide to vaccinators known as the Green Book.</p><p>For each new COVID-19 booster campaign the JCVI considers which groups should be recommended for a further booster. For the current spring campaign, the JCVI has recommended boosters were needed only for those at the very highest risk of serious outcomes. This covered those in care homes for older people, all those aged 75 years old or over and all those aged 5 or over who are immunosuppressed. The JCVI has advised that there should be a further booster programme in autumn 2023 for those at higher risk of severe COVID-19. Advice from the JCVI on which risk groups are recommended for a booster dose in autumn 2023 is expected ahead of autumn.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 27/06/2023 13:10:54 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4616 label Biography information for Rosie Duffield